Cancer Stem Cells and Biology
The cancer stem cell (CSCs) are distinguished as a small population of tumor cells which are able to form phenotypically diverse tumors, as wells as self-renew and differentiate. They are described as belonging to a group of tumor initiating cells (TICs) which may or may not possess stem-like characteristics, but debate remains as to how large a proportion of TICs are indeed stem-like. Additionally, it is not clear whether or not the plasticity of tumor cells allows any cell to become stem-like and gain the capability to recapitulate heterogeneous tumors. The role of CSCs in tumor formation was first identified by Bonnet and Dick in the late 90s .
Text under construction
Cancer Stem Cell Biology
Cancer Stem Cells (CSCs) are either formed upon carcinogenesis of somatic cells or stem cells, or they are activated after a period of dormancy (1). These CSCs then asymmetrically divide resulting in a phenotypically diverse tumor consisting of both CSCs and non-stem-like cells (2). Left untreated, the tumor will continue to grow and invade the surrounding tissue, and CSCs undergoing EMT may break off from the original tumor and travel to distant organs (3). The CSCs which reattach throughout the body can then initiate a new tumor, resulting in metastases (4). Using current treatment methods capable of inducing cell death in the bulk of tumor cells, the CSCs are not destroyed due to their enhanced survival traits, such as quiescence and the expression of ALDH enzymes and ABC transporters (5). The remaining CSCs may then go on to recreate the original tumor, sometimes increasing the percentage of CSCs within the tumor and forming multiple drug resistant tumors (6). In other cases, the remaining CSCs will enter a state of dormancy within the body and remain undetected for long periods of time before reactivating and initiating the formation of a new tumor, thus resulting in cancer relapse in patients thought to be cancer free (7). As a result of these issues, new treatments are being investigated which can target CSCs. Natural products have shown the potential to induce cell death in CSCs, cause CSCs to differentiate, or sensitize CSCs to conventional chemotherapy treatments (8). Once the CSCs have been eliminated, the remaining tumor may diminish in size and can be subsequently eradicated through the use of conventional antineoplastic therapies (9).
According to the CSC model, cancer recurrence after treatment is due to the superior resistance of CSCs to cellular toxins and insults. While current treatments are capable of eradicating the bulk of the tumor mass, the lingering CSCs are able to form new, fully developed tumors from a small number of cells or even a single cell. CSCs are thought to resist treatment through several cellular mechanisms including the overexpression of drug efflux pumps, quiescence, and detoxifying enzymes [12
]. A high population of CSCs within a tumor has subsequently been linked to MDR and a poorer prognosis for cancer patients [13
]. Furthermore, the cellular machinery of CSCs has been shown to allow for epithelial-mesenchymal transition (EMT), a process by which epithelial cells lose their cell-to-cell and/or cell-to-matrix adhesion and can survive in a migratory state [14
]. By undergoing EMT, migrating to other organs, and reattaching by mesenchymal-epithelial transition (MET), CSCs are hypothesized to initiate the formation of metastatic tumors.
Current methods for the treatment of cancer have been demonstrated to be insufficient in eliminating CSC populations from a number of cancer types. Glioma CSCs have been shown to resist radiation therapy . Breast CSCs exhibit a similar resistance to radiotherapy in addition to common chemotherapy treatments [16,17]. Furthermore, the CSC population in residual breast cancer tumors has been shown to increase significantly following chemotherapy treatments, nearly doubling the tumorigenic potential of the residual cancer cells in immunodeficient SCID mice .
Epithelial-mesenchymal transition (EMT) is the process undergone by epithelial cells in which the cells alter their morphology, lose their polarity, and break cell-cell or cell-matrix adhesions. In this way, the cells gain mobility and invasive potential. EMT is an essential process during development and wound healing, allowing epithelial cells to produce a population of mobile cells able to migrate to target locations and reestablish basal and apical polarity once there . CSCs are hypothesized to possess enhanced EMT capability, enabling the cells to survive in the absence of cellular adhesion in addition to enhancing their resistance to apoptosis. CSCs having undergone EMT are thought to then reattach and produce metastatic tumors or circulate throughout the body in a dormant state, only to become active years later and cause distant cancer relapse to occur. The ability of CSCs to undergo EMT can be investigated by determining the expression of EMT related proteins such as Twist, Snail, or N-cadherin .
More commonly, however, EMT capability is assessed by removing any opportunity for cellular attachment. This can be accomplished through the use of non-adherent well plates, stirred bioreactors, serum-free growth conditions, or encapsulation in hydrogels. When in these conditions, cells without EMT capability will die leaving only cells that have undergone the transition. The remaining cells often grow in what are referred to as tumorspheres which have been shown to be enriched in CSCs in numerous tissues [49–51]. A major drawback of using these selective growth environments is the relatively low purity of CSCs in the resulting population. Further, CSCs within tumorspheres of a large enough size are likely to differentiate into phenotypically diverse cells. Still, drug discovery efforts directed at limiting the EMT capability of CSCs should be encouraged as this ability lies at the heart of the spread and recurrence of cancer that plagues many patients.
Limitation of Conventional Oncology
Treatments targeting a specific molecule or surface marker are likely to fail to eliminate CSCs due to the multiple survival pathways activated in CSCs in addition to the ambiguity of CSC markers across different tissue types, the presence of commonly used CSC markers in healthy tissues, and the often required combination of markers used to denote CSC populations. Treatments capable of reducing CSC populations will therefore require the development of novel, diverse, and multi-targeted approaches for cancer treatment. Conventional oncology however has of yet not found any safe and efficient targeted treatment. A chicken antibiotic called salymicin is pending in clinical trial and seems to be the most promising substance to target cancer stem cells.
Drug resistance in cancer stem cells
While resistance to chemotherapy treatments is not necessary to define CSCs, drug resistance is commonly associated with CSC populations. In fact, when resistance to a drug is induced, an increase in the percentage of cells possessing CSC markers has been observed . Resistance to specific chemotherapy agents in cancer cell lines is typically promoted in vitro by exposing the cells to gradually increasing doses of the drug or by exposing the cells to several cycles of clinically relevant chemotherapy doses followed by drug free media to mimic the treatment patients actually receive. The enrichment of CSCs following chemotherapy regimens observed both in vitro and in clinical studies  has enormous implications on drug discovery efforts and future cancer treatment. Without the ability to target and kill CSCs, chemotherapy treatments will continue to leave patients at risk for tumor recurrence and developed drug resistance. The following proteins and properties of CSC are thought to contribute to drug resistance in CSCs and therefore represent ideal targets for future chemotherapy or chemotherapy sensitizing drug discovery efforts. It is important to note, however, that healthy stem cells share many of the properties imparting drug resistance to CSCs, and as a result targeting these properties may lead to unwanted side-effects on otherwise healthy tissues.
ATP-binding cassette (ABC) transporters are transmembrane proteins that serve a crucial cytoprotective role for healthy stem cells throughout the body. The function of these proteins is to pump toxic compounds from the cell body before their deleterious effects can occur. These pumps are able to act on a large variety of compounds including many chemotherapeutic agents. The expression of ABC transporters has been used to indicate CSC phenotypes in multiple tissues and also plays a role in developing the multiple drug resistance (MDR) typical of CSCs . Members of the ABC transporter family that appear to be highly expressed in CSCs include, but are not limited to, ABCB1, ABCG2, and ABCB5 . The expressions of these proteins have been suggested as markers for CSCs, but the lack of appropriate antibodies makes their detection more difficult than previously discussed markers. The ability of the SP to exclude Hoescht 33342 is a result of ABC transporters, specifically ABCG2, making SP isolation an indirect method of CSC isolation based upon ABC transporter expression .
Many of the ABC transporter proteins have been “discovered” multiple times in the context of chemotherapy resistance leading to confusion in their identification. For example, ABCG2 is often referred to as breast cancer resistance protein (BCRP) alluding to its ability to confer MDR to breast tumor cells. ABCG2 expression has been identified in the drug resistant subpopulations of many cancer models including K562 chronic myeloid leukemia cells  and MCF7 breast adenocarcinoma to name a few . The cell lines in these experiments were made resistant through selection with various chemotherapies such as doxorubicin.
ABCB1 is another ABC transporter with multiple aliases. ABCB1 has been referred to by the names multidrug resistance protein 1 (MDR1), cluster of differentiation 243 (CD243), and most commonly P-glycoprotein 1 (P-gp). ABCB1 contributes to the efflux of many widely used chemotherapeutic agents including anthracyclines, vinca alkaloids, and taxanes making it a highly clinically relevant MDR protein . Reduction of the expression of ABCB1 has been shown to lead to an increased chemotherapy sensitivity of colorectal CSCs in addition to MDR cell lines of differing origin . By targeting ABC transporters, the unique resistance of CSCs can theoretically be reversed, sensitizing them to traditional chemotherapy treatments.
Another strategy CSCs employ in order to exhibit MDR is the rapid metabolization of the chemotherapy agents they are subjected to. As mentioned previously, the presence of ALDH enzymes and their activity is a commonly used marker to identify CSCs. ALDH enzymes exert their effect by oxidizing aldehyde groups of drug molecules, preparing them for future cell metabolism and thus detoxifying the cell. ALDH enzymes may also play a role in the differentiation of healthy and malignant stem cells. Inhibition of ALDH activity in ALDHhi/CD44+ putative breast CSCs convincingly resulted in a loss of MDR . Interestingly, the inhibition of ALDH activity using diethylaminobenzaldehyde (DEAB) further sensitized these CSCs to radiation therapy. By eliminating ALDH activity from tumors, the breakdown of chemotherapeutic agents within the tumor will be slowed resulting in a more effective treatment. Cytotoxic compounds which do not act as substrates for ALDH enzymes or that reduce their activity may have a unique ability to induce apoptosis in CSCs and act as more effective long-term treatments.
Pro-survival signaling and stem cell maintenance
CSCs hijack many of the pro-survival signaling cascades and maintenance proteins seen in healthy stem cells. In this way, CSCs have a tendency to survive cellular stresses capable of eliminating differentiated cancer cells in a similar fashion to non-malignant stem cells. For example, mechanistic target of rapamycin (mTOR) and signal transducer and activator of transcription 3 (STAT3) play a role in the maintenance and proliferation of healthy and cancer stem cells. The activation of phosphatase and tensin homolog (PTEN) and subsequent inhibition of mTOR and STAT3 results in a significant decrease in CSC viability and overall tumor drug resistance .
The stem cell maintenance proteins Wnt, Hedgehog, and Notch are also upregulated in CSCs. These molecules play a major role in maintaining the stem-ness of CSCs and activating the expression of stem cell related transcription factors such as octamer-binding transcription factor (Oct4) and Nanog as well as influencing EMT . Stem cell maintenance proteins such as these ensure CSCs will continue to asymmetrically divide, allowing the CSC phenotype to persist in a number of harsh conditions. Dysregulation of these pathways is hypothesized to promote gradual CSC differentiation leading to decreased tumor viability in response to chemotherapeutics, making them an attractive target for the treatment of both bulk tumors and CSCs.
Cellular quiescence is defined by a reduced occurrence of mitotic divisions within a cell population. Quiescence is recognized as a trait of most somatic stem cells, allowing them to survive in a state of relative dormancy and reduce the accumulation of DNA mutations over time . While debate remains as to whether or not chemotherapy agents have a diminished effect on quiescent cells, experiments on leukemia stem cells have shown that forcing these cells out of their dormant state results in increased drug sensitivity . The hypothesis behind this pathway for MDR is that diminished cellular metabolism, failure to proceed throughout the entirety of the cell cycle, and lack of DNA multiplication allows CSCs to avoid activating the targets of many chemotherapeutic toxins. Quiescence of CSCs not only potentially influences MDR, but also enables CSCs to remain dormant at the site of the original lesion or migrate throughout the body for years before attaching and initiating new tumors. Targeting the quiescence of CSCs has the potential to increase the efficacy of current therapeutic methods against CSCs within the original tumor as well as prevent CSCs from entering dormant states capable of initiating new tumors in patients in remission.
1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–737. [PubMed]
2. Velasco-Velaquez MA, Homsi N, De La Fuente M. Breast cancer stem cells. Int J Biochem Cell Biol. 2012;44:537–577.
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–3988. [PMC free article][PubMed]
4. O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106–110. [PubMed]
5. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007;104:973–978. [PMC free article] [PubMed]
6. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun. 2006;351:820–824. [PubMed]
7. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, Nakauchi H, Taniguchi H. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006;44:240–251. [PubMed]
8. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15:504–514. [PubMed]
9. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A. 2006;103:11154–11159. [PMC free article] [PubMed]
10. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2-cancer cells are similarly tumorigenic. Cancer Res. 2005;65:6207–6219. [PubMed]
11. Li C, Lee CJ, Simeone DM. Identification of human pancreatic cancer stem cells. Methods Mol Biol. 2009;568:161–173. [PubMed]
12. Zhang Q, Feng Y, Kennedy D. Multidrug-resistant cancer cells and cancer stem cells hijack cellular systems to circumvent systemic therapies, can natural products reverse this? Cell Mol Life Sci. 2017;74:777–801. [PubMed]
13. Lee HE, Kim JH, Kim YJ, Choi SY, Kim SW, Kang E, Chung IY, Kim IA, Kim EJ, Choi Y, Ryu HS, Park SY. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer. 2011;104:1730–1738. [PMC free article] [PubMed]
14. Radisky DC. Epithelial-mesenchymal transition. J Cell Sci. 2005;118:4325–4326. [PubMed]
15. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–760. [PubMed]
16. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancerinitiating cells to radiation. J Natl Cancer Inst. 2006;98:1777–1785. [PubMed]
17. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100:672–679. [PubMed]
18. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66:9339–9344. [PubMed]
19. Hwang-Verslues WW, Kuo WH, Chang PH, Pan CC, Wang HH, Tsai ST, Jeng YM, Shew JY, Kung JT, Chen CH, Lee EY, Chang KJ, Lee WH. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One. 2009;4:e8377. [PMC free article] [PubMed]
20. Leishman A, Fairchild PJ. Differentiation of dendritic cells from human induced pluripotent stem cells. Stem cells and cancer stem cells. 2013;12:29–37.
21. Rao CV, Mohammed A. New insights into pancreatic cancer stem cells. World J Stem Cells. 2015;7:547–555. [PMC free article] [PubMed]
22. Chan KS, Volkmer JP, Weissman I. Cancer stem cells in bladder cancer: a revisited and evolving concept. Curr Opin Urol. 2010;20:393–397. [PMC free article] [PubMed]
23. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer. 2010;46:1271–1277. [PubMed]
24. Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011;11:254–267. [PubMed]
25. Vira D, Basak SK, Veena MS, Wang MB, Batra RK, Srivatsan ES. Cancer stem cells, microRNAs, and therapeutic strategies including natural products. Cancer Metastasis Rev. 2012;31:733–751. [PubMed]
26. Cheng JX, Liu BL, Zhang X. How powerful is CD133 as a cancer stem cell marker in brain tumors? Cancer Treat Rev. 2009;35:403–408. [PubMed]
27. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR, Berchuck A, Murphy SK. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene. 2009;28:209–218. [PubMed]
28. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancuso S, Scambia G. Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer. 2008;18:506–514. [PubMed]
29. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313–323. [PubMed]
30. Horst D, Scheel SK, Liebmann S, Neumann J, Maatz S, Kirchner T, Jung A. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol. 2009;219:427–434. [PubMed]
31. Yiming L, Yunshan G, Bo M, Yu Z, Tao W, Gengfang L, Dexian F, Shiqian C, Jianli J, Juan T, Zhinan C. CD133 overexpression correlates with clinicopathological features of gastric cancer patients and its impact on survival: a systematic review and meta-analysis. Oncotarget. 2015;6:42019–42027.[PMC free article] [PubMed]
32. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer. 2008;98:756–765. [PMC free article] [PubMed]
33. Fang X, Zheng P, Tang J, Liu Y. CD24: from A to Z. Cell Mol Immunol. 2010;7:100–103.[PMC free article] [PubMed]
34. Kristiansen G, Schlüns K, Yongwei Y, Denkert C, Dietel M, Petersen I. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer. 2003;88:231–236.[PMC free article] [PubMed]
35. Kwon MJ, Han J, Seo JH, Song K, Jeong HM, Choi JS, Kim YJ, Lee SH, Choi YL, Shin YK. CD24 overexpression is associated with poor prognosis in luminal a and triple-negative breast cancer. PLoS One. 2015;10:e0139112. [PMC free article] [PubMed]
36. Kristiansen G, Denkert C, Schlüns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol. 2002;161:1215–1221.[PMC free article] [PubMed]
37. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007;104:10158–10163. [PMC free article] [PubMed]
38. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, Cole DJ, Gillanders WE. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 2004;64:5818–5824. [PubMed]
39. Armstrong L, Stojkovic M, Dimmick I, Ahmad S, Stojkovic P, Hole N, Lako M. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells. 2004;22:1142–1151. [PubMed]
40. Corti S, Locatelli F, Papadimitriou D, Donadoni C, Salani S, Del Bo R, Strazzer S, Bresolin N, Comi GP. Identification of a primitive brainderived neural stem cell population based on aldehyde dehydrogenase activity. Stem Cells. 2006;24:975–985. [PubMed]
41. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009;69:3382–3389. [PMC free article][PubMed]
42. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci F, Jacquemier J, Xerri L, Dontu G, Stassi G, Xiao Y, Barsky SH, Birnbaum D, Viens P, Wicha MS. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 2010;16:45–55. [PMC free article] [PubMed]
43. Chen YC, Chen YW, Hsu HS, Tseng LM, Huang PI, Lu KH, Chen DT, Tai LK, Yung MC, Chang SC, Ku HH, Chiou SH, Lo WL. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun. 2009;385:307–313. [PubMed]
44. Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010;9:3186–3199.[PMC free article] [PubMed]
45. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA, Katz RL. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 2009;7:330–338. [PMC free article] [PubMed]
46. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996;183:1797–1806.[PMC free article] [PubMed]
47. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007;67:4827–4833. [PubMed]
48. Dave B, Mittal V, Tan NM, Chang JC. Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res. 2012;14:202. [PMC free article] [PubMed]
49. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005;65:5506–5511. [PubMed]
50. Cao L, Zhou Y, Zhai B, Liao J, Xu W, Zhang R, Li J, Zhang Y, Chen L, Qian H, Wu M, Yin Z. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol. 2011;11:71. [PMC free article] [PubMed]
51. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007;67:4010–4015. [PubMed]
52. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G, Samuel S, Kim MP, Lim SJ, Ellis LM. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 2009;69:1951–1957. [PMC free article] [PubMed]
53. Moitra K. Overcoming Multidrug Resistance in Cancer Stem Cells. Biomed Res Int. 2015;2015:635745. [PMC free article] [PubMed]
54. Moitra K, Lou H, Dean M. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther. 2011;89:491–502. [PubMed]
55. Daflon-Yunes N, Pinto-Silva FE, Vidal RS, Novis BF, Berguetti T, Lopes RR, Polycarpo C, Rumjanek VM. Characterization of a multidrugresistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms. Mol Cell Biochem. 2013;383:123–135. [PubMed]
56. Nakanishi T, Bailey-Dell KJ, Hassel BA, Shiozawa K, Sullivan DM, Turner J, Ross DD. Novel 5’ untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissuespecific expression, and alternative promoter usage. Cancer Res. 2006;66:5007–5011. [PubMed]
57. Katayama K, Noguchi K, Sugimoto Y. Regulations of P-glycoprotein/ABCB1/MDR1 in human cancer cells. New Journal of Science. 2014:1–10.
58. Croker AK, Allan AL. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stemlike ALDHhiCD44+ human breast cancer cells. Breast Cancer Res Treat. 2012;133:75–87. [PubMed]
59. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, Margolick JB, Liotta LA, Petricoin E, Zhang Y. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A. 2007;104:16158–16163. [PMC free article] [PubMed]
60. Cochrane CR, Szczepny A, Watkins DN, Cain JE. Hedgehog signaling in the maintenance of cancer stem cells. Cancers (Basel) 2015;7:1554–1585. [PMC free article] [PubMed]
61. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17:313–319.[PubMed]
62. Borst P. Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol. 2012;2:120066. [PMC free article][PubMed]
63. Petrovska BB. Historical review of medicinal plants’ usage. Pharmacogn Rev. 2012;6:1–5.[PMC free article] [PubMed]
64. Solecki RS. Shanidar IV, a Neanderthal flower burial in Northern Iraq. Science. 1975;190:880–881.
65. Robinson MM, Zhang X. The World Medicines Situation 2011. Geneva, Switzerland: WHO Press; 2011. Traditional medicines: global situation, issues and challenges.
66. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007;70:461–477. [PubMed]
67. Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25:2677–2681.[PMC free article] [PubMed]
68. Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci. 2005;78:431–441.[PubMed]
69. Jantan I, Bukhari SNA, Mohamed MAS, Wai LK, Mesaik MA. The evolving role of natural products from the tropical rainforests as a replenishable source of new drug leads. In: Vallisuta PO, editor. Drug discovery and development-from molecules to medicine. InTech; 2015.
70. Basmadjian C, Zhao Q, Bentouhami E, Djehal A, Nebigil CG, Johnson RA, Serova M, de Gramont A, Faivre S, Raymond E, Désaubry LG. Cancer wars: natural products strike back. Front Chem. 2014;2:20.[PMC free article] [PubMed]
71. Szymański P, Markowicz M, Mikiciuk-Olasik E. Adaptation of high-throughput screening in drug discovery-toxicological screening tests. Int J Mol Sci. 2012;13:427–452. [PMC free article] [PubMed]
72. Mishra BB, Tiwari VK. Natural products: an evolving role in future drug discovery. Eur J Med Chem. 2011;46:4769–4807. [PubMed]
73. Arya R, Bhutkar S, Dhulap S, Hirwani RR. Patent analysis as a tool for research planning: study on natural based therapeutics against cancer stem cells. Recent Pat Anticancer Drug Discov. 2015;10:72–86.[PubMed]
74. Marucci C, Fumagalli G, Calogero F, Silvani A, Christodoulou MS, Martinet N, Passarella D. Natural products and cancer stem cells. Curr Pharm Des. 2015;21:5547–5557. [PubMed]
75. Weng CJ, Yen GC. Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: phenolic acids, monophenol, polyphenol, and their derivatives. Cancer Treat Rev. 2012;38:76–87. [PubMed]
76. Scarlatti F, Sala G, Somenzi G, Signorelli P, Sacchi N, Ghidoni R. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J. 2003;17:2339–2341. [PubMed]
77. Opipari AW, Tan L, Boitano AE, Sorenson DR, Aurora A, Liu JR. Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res. 2004;64:696–703. [PubMed]
78. Shankar S, Nall D, Tang SN, Meeker D, Passarini J, Sharma J, Srivastava RK. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One. 2011;6:e16530.[PMC free article] [PubMed]
79. Pandey PR, Okuda H, Watabe M, Pai SK, Liu W, Kobayashi A, Xing F, Fukuda K, Hirota S, Sugai T, Wakabayashi G, Koeda K, Kashiwaba M, Suzuki K, Chiba T, Endo M, Fujioka T, Tanji S, Mo YY, Cao D, Wilber AC, Watabe K. Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res Treat. 2011;130:387–398. [PMC free article] [PubMed]
80. Singh CK, Ndiaye MA, Ahmad N. Resveratrol and cancer: Challenges for clinical translation. Biochim Biophys Acta. 2015;1852:1178–1185. [PMC free article] [PubMed]
81. Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: What formulation solutions to bioavailability limitations? J Control Release. 2012;158:182–193. [PubMed]
82. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A. Polymeric nanoparticle-encapsulated curcumin (“nanocurcumin”): a novel strategy for human cancer therapy. J Nanobiotechnology. 2007;5:3.[PMC free article] [PubMed]
83. Epelbaum R, Vizel B, Bar-Sela G. Phase II study of curcumin and gemcitabine in patients with advanced pancreatic cancer. Journal of Clinical Oncology. 2008:26.
84. Kakarala M, Brenner DE, Korkaya H, Cheng C, Tazi K, Ginestier C, Liu S, Dontu G, Wicha MS. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat. 2010;122:777–785. [PMC free article] [PubMed]
85. Lin L, Liu Y, Li H, Li PK, Fuchs J, Shibata H, Iwabuchi Y, Lin J. Targeting colon cancer stem cells using a new curcumin analogue, GOY030. Br J Cancer. 2011;105:212–220. [PMC free article] [PubMed]
86. Yu Y, Kanwar SS, Patel BB, Nautiyal J, Sarkar FH, Majumdar AP. Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX. Transl Oncol. 2009;2:321–328.[PMC free article] [PubMed]
87. Wahlström B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh) 1978;43:86–92. [PubMed]
88. Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos. 1999;27:486–494. [PubMed]
89. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci. 2009;30:85–94. [PubMed]
90. Galati G, O’Brien PJ. Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. Free Radic Biol Med. 2004;37:287–303. [PubMed]
91. Middleton E, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev. 2000;52:673–751. [PubMed]
92. Lamson DW, Brignall MS. Antioxidants and cancer, part 3: quercetin. Altern Med Rev. 2000;5:196–208. [PubMed]
93. Atashpour S, Fouladdel S, Movahhed TK, Barzegar E, Ghahremani MH, Ostad SN, Azizi E. Quercetin induces cell cycle arrest and apoptosis in CD133(+) cancer stem cells of human colorectal HT29 cancer cell line and enhances anticancer effects of doxorubicin. Iran J Basic Med Sci. 2015;18:635–643.[PMC free article] [PubMed]
94. Tang SN, Singh C, Nall D, Meeker D, Shankar S, Srivastava RK. The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal. 2010;5:14. [PMC free article][PubMed]
95. Cai X, Fang Z, Dou J, Yu A, Zhai G. Bioavailability of quercetin: problems and promises. Curr Med Chem. 2013;20:2572–2582. [PubMed]
96. Lu JJ, Bao JL, Chen XP, Huang M, Wang YT. Alkaloids isolated from natural herbs as the anticancer agents. Evid Based Complement Alternat Med. 2012;2012:485042. [PMC free article] [PubMed]
97. Beljanski M, Beljanski MS. Selective inhibition of in vitro synthesis of cancer DNA by alkaloids of beta-carboline class. Exp Cell Biol. 1982;50:79–87. [PubMed]
98. Oh SH, Kim YS, Lim SC, Hou YF, Chang IY, You HJ. Dihydrocapsaicin (DHC), a saturated structural analog of capsaicin, induces autophagy in human cancer cells in a catalaseregulated manner. Autophagy. 2008;4:1009–1019. [PubMed]
99. Yaffe PB, Power Coombs MR, Doucette CD, Walsh M, Hoskin DW. Piperine, an alkaloid from black pepper, inhibits growth of human colon cancer cells via G1 arrest and apoptosis triggered by endoplasmic reticulum stress. Mol Carcinog. 2015;54:1070–1085. [PubMed]
100. Samykutty A, Shetty AV, Dakshinamoorthy G, Bartik MM, Johnson GL, Webb B, Zheng G, Chen A, Kalyanasundaram R, Munirathinam G. Piperine, a bioactive component of pepper spice exerts therapeutic effects on androgen dependent and androgen independent prostate cancer cells. PLoS One. 2013;8:e65889.[PMC free article] [PubMed]
101. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008;269:199–225. [PubMed]
102. Meeran SM, Katiyar S, Katiyar SK. Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation. Toxicol Appl Pharmacol. 2008;229:33–43. [PubMed]
103. Iizuka N, Miyamoto K, Okita K, Tangoku A, Hayashi H, Yosino S, Abe T, Morioka T, Hazama S, Oka M. Inhibitory effect of Coptidis Rhizoma and berberine on the proliferation of human esophageal cancer cell lines. Cancer Lett. 2000;148:19–25. [PubMed]
104. Ma X, Zhou J, Zhang CX, Li XY, Li N, Ju RJ, Shi JF, Sun MG, Zhao WY, Mu LM, Yan Y, Lu WL. Modulation of drug-resistant membrane and apoptosis proteins of breast cancer stem cells by targeting berberine liposomes. Biomaterials. 2013;34:4452–4465. [PubMed]
105. Gillis JC, Goa KL. Tretinoin. A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia. Drugs. 1995;50:897–923. [PubMed]
106. Gudas LJ, Wagner JA. Retinoids regulate stem cell differentiation. J Cell Physiol. 2011;226:322–330.[PMC free article] [PubMed]
107. Ginestier C, Wicinski J, Cervera N, Monville F, Finetti P, Bertucci F, Wicha MS, Birnbaum D, Charafe-Jauffret E. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle. 2009;8:3297–3302. [PMC free article] [PubMed]
108. Wallen E, Sellers RG, Peehl DM. Brefeldin A induces p53-independent apoptosis in primary cultures of human prostatic cancer cells. J Urol. 2000;164:836–841. [PubMed]
109. Shao RG, Shimizu T, Pommier Y. Brefeldin A is a potent inducer of apoptosis in human cancer cells independently of p53. Exp Cell Res. 1996;227:190–196. [PubMed]
110. Tseng CN, Hong YR, Chang HW, Yu TJ, Hung TW, Hou MF, Yuan SS, Cho CL, Liu CT, Chiu CC, Huang CJ. Brefeldin A reduces anchorageindependent survival, cancer stem cell potential and migration of MDA-MB-231 human breast cancer cells. Molecules. 2014;19:17464–17477. [PubMed]
111. Tseng CN, Huang CF, Cho CL, Chang HW, Huang CW, Chiu CC, Chang YF. Brefeldin a effectively inhibits cancer stem cell-like properties and MMP-9 activity in human colorectal cancer Colo 205 cells. Molecules. 2013;18:10242–10253. [PubMed]